Ashton Thomas Private Wealth LLC Cuts Position in Zoetis Inc. $ZTS

Key Points

• Ashton Thomas Private Wealth LLC has reduced its stake in Zoetis Inc. by 18.0%, selling 5,682 shares and now holding 25,870 shares worth approximately $4.26 million.
• Zoetis reported a quarterly earnings per share (EPS) of $1.76, beating the consensus estimate, with revenue of $2.46 billion indicating a 4.2% year-over-year increase.
• Analysts have a consensus rating of "Moderate Buy" on Zoetis, with a target price averaging $202.43, despite some recent downgrades from various brokerages.

Ashton Thomas Private Wealth LLC trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 18.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,870 shares of the company's stock after selling 5,682 shares during the period. Ashton Thomas Private Wealth LLC's holdings in Zoetis were worth $4,260,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. 1248 Management LLC bought a new position in Zoetis during the first quarter worth about $27,000. Saudi Central Bank purchased a new position in Zoetis during the 1st quarter worth $29,000. Cornerstone Planning Group LLC boosted its holdings in shares of Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after buying an additional 88 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its stake in Zoetis by 87.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after acquiring an additional 120 shares during the period. Finally, Sound Income Strategies LLC lifted its holdings in shares of Zoetis by 141.4% in the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after buying an additional 164 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Up 0.8%

Zoetis stock traded up $1.24 during mid-day trading on Thursday, hitting $150.66. 3,193,921 shares of the company's stock were exchanged, compared to its average volume of 2,247,475. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock has a market cap of $66.77 billion, a P/E ratio of 25.93, a P/E/G ratio of 2.40 and a beta of 0.89. The stock has a 50 day moving average of $152.70 and a two-hundred day moving average of $157.56.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company's revenue was up 4.2% compared to the same quarter last year. During the same period in the previous year, the business earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and reduced their target price for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Piper Sandler raised their target price on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Finally, Argus reiterated a "buy" rating and issued a $190.00 target price on shares of Zoetis in a report on Tuesday. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.